Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 3/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427827 | 0.90 | DOCK5 (0.52) | HPGDTSHRMETAP2DOCK5 | |
| SCHEMBL14359510 | 0.84 | TSHR (0.52) | HPGDTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL5429876 | 0.83 | DOCK5 (0.49) | HPGDTSHRMETAP2DOCK5 | |
| SCHEMBL5437278 | 0.83 | CYP1A2 (0.37) | TSHRMETAP2RORCALDH1A1KMT2A | |
| SCHEMBL5430012 | 0.83 | CYP3A4 (0.54) | HPGDTSHRALDH1A1KMT2A | |
| SCHEMBL5423572 | 0.82 | L3MBTL1 (0.42) | METAP2MAPTDOCK5 | |
| SCHEMBL5429871 | 0.82 | METAP2 (0.47) | TSHRMETAP2ALDH1A1 | |
| SCHEMBL5427031 | 0.81 | CYP3A4 (0.55) | TSHRALDH1A1KMT2A | |
| SCHEMBL5426870 | 0.81 | DOCK5 (0.55) | METAP2DOCK5KMT2A | |
| SCHEMBL5418480 | 0.80 | CYP3A4 (0.40) | TSHRMETAP2RORCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | ONO PHARMACEUTICAL CO., LTD. | 2007-11-29 | — | — | US | disclosed |
| EP-1683797-A1 | HETEROCYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | NR3C2, CBR1, CBR3 | HPGD 115/4885TSHR 254/4885CTSG 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.